FDA warns Zoll about battery life for defibrillators
July 11, 2011 by MassDevice staff
The FDA says Zoll medical failed to demonstrate that they properly validate battery life for their automated external defibrillators after more than a dozen complaints.
The U.S. Food & Drug Administrations filed a warnings against ZOLL Medical Corporation (NSDQ:ZOLL) for allegedly failing to validate battery life cycles for its external defibrillators.
Zoll has logged 15 complaints between September 2009 and January 2011 alleging that the batteries in the Chelmsford, Mass.-based company's automated external defibrillators died prior to their 5-year expectations, the agency said in its letter.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Mobilizing on the back end of a disaster
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
Navigation
NEWS
Medical device tax: Consultant calls offshoring concerns 'horse hockey'
Concerns that the medical device tax will push companies to lay off workers and move operations...
FDA clears OrthoSensor's Verasense knee replacement device
The FDA clears OrthoSensor's Verasense device, designed to help surgeons fit knee replacement...
ArtVentive Medical wins CE Mark for peripheral catheter
ArtVentive Medical Group wins CE Mark approval in the European Union for its EOS peripheral vascular...
Recalls: FDA makes Endologix catheter introducer recall Class I
The FDA hits Endologix's catheter introducer device recall with Class I status, its most serious...
pSivida gains big on buyout rumor
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology...
